The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Treatment of epithelial ovarian cancer
Open accessAbstract
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts for the highest mortality rate among these cancers. A stepwise approach to assessment, diagnosis, and treatment is vital to appropriate management of this disease process. An integrated approach with gynecologic oncologists as well as medical oncologists, pathologists, and radiologists is of paramount importance to improving outcomes. Surgical cytoreduction to R0 is the mainstay of treatment, followed by adjuvant chemotherapy. Genetic testing for gene mutations that affect treatment is the standard of care for all women with epithelial ovarian cancer. Nearly all women will have a recurrence, and the treatment of recurrent ovarian cancer continues to be nuanced and requires extensive review of up to date modalities that balance efficacy with the patient’s quality of life. Maintenance therapy with poly ADP-ribose polymerase inhibitors, bevacizumab, and/or drugs targeting homologous recombination deficiency is becoming more widely used in the treatment of ovarian cancer, and the advancement of immunotherapy is further revolutionizing treatment targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
International Agency for Research on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/pfg7jq · Cited by 9,435
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Bakitas, M. A., Tosteson, T. D., Li, Z., Lyons, K. D., Hull, J. G., Li, Z., Dionne-Odom, J. N., Frost, J., Dragnev, K. H., Hegel, M. T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.6362 · Cited by 1,216
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30388-2 · Cited by 1,159
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913
Chow, W. B., Rosenthal, R. A., Merkow, R. P., Ko, C. Y., & Esnaola, N. F. (2012) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2012.06.017 · Cited by 902
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Inherited Mutations in Women With Ovarian Carcinoma
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Yi, Q., Burger, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5495 · Cited by 769
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1684 · Cited by 705
Trimbos, J. B., Vergote, I., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.113 · Cited by 674
Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S. B., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh323 · Cited by 632
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Harter, P., Sehouli, J., Lorusso, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1808424 · Cited by 594
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., & Major, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221501 · Cited by 583
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Konstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1048 · Cited by 563
Redefining Geriatric Preoperative Assessment Using Frailty, Disability and Co-Morbidity
Robinson, T. N., Eiseman, B., Wallace, J. I., Church, S. D., McFann, K. K., Pfister, S. M., Sharp, T. J., & Moss, M. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b45598 · Cited by 543
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30029-4 · Cited by 533
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Tewari, K. S., Burger, R. A., Enserro, D., Norquist, B. M., Swisher, E. M., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H., Homesley, H. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01009 · Cited by 483
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Panici, P. B., Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K., Winter, R., Pellegrino, A., Greggi, S., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji102 · Cited by 465
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help
(2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.11.001 · Cited by 463
Markman, M., Liu, P. Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., & Alberts, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447
Chang, S.-J., Hodeib, M., Chang, J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 433
Salani, R., Backes, F. J., Fung Kee Fung, M., Holschneider, C. H., Parker, L. P., Bristow, R. E., & Goff, B. A. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.03.008 · Cited by 428
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6907 · Cited by 409
Optimal primary surgical treatment for advanced epithelial ovarian cancer
Elattar, A., Bryant, A., Winter-Roach, B. A., Hatem, M., & Naik, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007565.pub2 · Cited by 403
Fagotti, A., Ferrandina, G., Vizzielli, G., Fanfani, F., Gallotta, V., Chiantera, V., Costantini, B., Margariti, P. A., Gueli Alletti, S., Cosentino, F., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.017 · Cited by 395
Gaertner, J., Siemens, W., Meerpohl, J. J., Antes, G., Meffert, C., Xander, C., Stock, S., Mueller, D., Schwarzer, G., & Becker, G. (2017) · BMJ · doi:10.1136/bmj.j2925 · Cited by 393
Gore, M. E., Fryatt, I., Wiltshaw, E., & Dawson, T. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90174-j · Cited by 381
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.022 · Cited by 362
Zamarin, D., Burger, R. A., Sill, M. W., Powell, D. J., Lankes, H. A., Feldman, M. D., Zivanovic, O., Gunderson, C., Ko, E., Mathews, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02059 · Cited by 345
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Fagotti, A., Ferrandina, G., Fanfani, F., Garganese, G., Vizzielli, G., Carone, V., Salerno, M. G., & Scambia, G. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.06.052 · Cited by 315
Efficiencies of platform clinical trials: A vision of the future
Saville, B. R., & Berry, S. M. (2016) · Clinical Trials · doi:10.1177/1740774515626362 · Cited by 315
Survival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian Cancer
井上, 隆., Montz, F. J., Lagasse, L. D., Leuchter, R. S., & Karlan, B. Y. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5145 · Cited by 308
Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., & Spirtos, N. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.013 · Cited by 307
Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., Jayson, G. C., Johnson, N., Swart, A. M., Verheijen, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30566-7 · Cited by 306
Salani, R., Khanna, N., Frimer, M., Bristow, R. E., & Chen, L.-M. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.03.022 · Cited by 291
Tewari, D., Java, J. J., Salani, R., Armstrong, D. K., Markman, M., Herzog, T., Monk, B. J., & Chan, J. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9898 · Cited by 288
Varga, A., Piha-Paul, S., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., Yang, P., Ruman, J., & Matei, D. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.11.017 · Cited by 280
CA 125, PET alone, PET–CT, CT and MRI in diagnosing recurrent ovarian carcinoma
Gu, P., Pan, L.-L., Wu, S.-Q., Sun, L., & Huang, G. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.02.019 · Cited by 265
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Luvero, D., Milani, A., & Ledermann, J. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014544121 · Cited by 260
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Wang, Z., Sun, K., Xiao, Y., Feng, B., Mikule, K., Ma, X., Feng, N., Vellano, C. P., Federico, L., Marszalek, J. R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38534-6 · Cited by 253
Markman, M., Blessing, J., Rubin, S. C., Connor, J., Hanjani, P., & Waggoner, S. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.036 · Cited by 237
Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., DiSilvestro, P. A., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01568 · Cited by 231
Liu, J. F., Herold, C., Gray, K. P., Penson, R. T., Horowitz, N., Konstantinopoulos, P. A., Castro, C. M., Hill, S. J., Curtis, J., Luo, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3343 · Cited by 222
Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J.-W., O'Donnell, D. M., Hook, J., Coyle, C., Blagden, S., Brenton, J. D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32259-7 · Cited by 209
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer
Lawrie, T. A., Winter-Roach, B. A., Heus, P., & Kitchener, H. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004706.pub5 · Cited by 204
Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L., & Cella, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3494 · Cited by 197
Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M. C., Fossati, R., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.307 · Cited by 189
A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer
Covens, A. L. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5926 · Cited by 183
Hereditary ovarian cancer: Beyond the usual suspects
Pennington, K. P., & Swisher, E. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.12.415 · Cited by 182
Du Bois, A., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Jensen, P. T., Selle, F., Guyon, F., Pomel, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5501 · Cited by 176
Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized Trial
Trimbos, B., Timmers, P., Pecorelli, S., Coens, C., Ven, K., van der Burg, M., & Casado, A. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq149 · Cited by 172
Fukuse, T., Satoda, N., Hijiya, K., & Takuji, F. (2005) · Chest · doi:10.1378/chest.127.3.886 · Cited by 171
Bristow, R. E., Chang, J., Ziogas, A., Randall, L. M., & Anton-Culver, H. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.017 · Cited by 171
Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq352 · Cited by 163
O’Malley, D. M., Matulonis, U. A., Birrer, M. J., Castro, C. M., Gilbert, L., Vergote, I. B., Martin, L. P., Mantia-Smaldone, G. M., González-Martín, A., Bratos, R., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.037 · Cited by 159
Frey, M. K., & Pothuri, B. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0039-8 · Cited by 151
Chan, J. K., Tian, C., Fleming, G. F., Monk, B. J., Herzog, T. J., Kapp, D. S., & Bell, J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.073 · Cited by 148
Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.04.555 · Cited by 131
Markman, M. M., Liu, P., Moon, J., Monk, B. J., Copeland, L. J., Wilczynski, S. P., & Alberts, D. S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.04.012 · Cited by 126
Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours
Coon, M. E., Stephan, S. B., Gupta, V., Kealey, C. P., & Stephan, M. T. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0486-0 · Cited by 119
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, É., Park, Y. C., Parekh, T. V., & Poveda, A. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.001 · Cited by 95
Pignata, S., Scambia, G., Bologna, A., Signoriello, S., Vergote, I. B., Wagner, U. A. G., Lorusso, D., Murgia, V., Sorio, R., Ferrandina, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4293 · Cited by 87
Gómez-Hidalgo, N. R., Martínez-Cannon, B. A., Nick, A. M., Lu, K. H., Sood, A. K., Coleman, R. L., & Ramirez, P. T. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.049 · Cited by 85
Ferriss, J. S., Java, J., Bookman, M. A., Fleming, G. F., Monk, B. J., Walker, J. L., Homesley, H. D., Fowler, J. M., Greer, B. E., Boente, M. P., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.07.103 · Cited by 83
Raja, F. A., Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M., Vergote, I. B., González-Martı́n, A., Alberts, D. S., Plante, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt406 · Cited by 82
von Gruenigen, V. E., Huang, H. Q., Beumer, J. H., Lankes, H. A., Tew, W. P., Herzog, T. J., Hurria, A., Mannel, R. S., Rizack, T., Landrum, L. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.033 · Cited by 81
Surveillance of patients after initial treatment of ovarian cancer
Gadducci, A., & Cosio, S. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.12.008 · Cited by 79
Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature
Trope, C. G., & Kærn, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1013 · Cited by 76
Pignata, S., Lorusso, D., Joly, F., Gallo, C., Colombo, N., Sessa, C., Bamias, A., Pisano, C., Selle, F., Zaccarelli, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5506 · Cited by 74
Mannel, R. S., Brady, M. F., Kohn, E. C., Hanjani, P., Hiura, M., Lee, R., DeGeest, K., Cohn, D. E., Monk, B. J., & Michael, H. T. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.03.013 · Cited by 70
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer
Winter-Roach, B. A., Kitchener, H. C., & Dickinson, H. O. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004706.pub3 · Cited by 68
The follow-up of ovarian cancer
Vaidya, A. P., & Curtin, J. P. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00100-3 · Cited by 62
Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S. Y. T., Filipczyk−Cisarż, E., Hagberg, H., Vergote, I. B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq353 · Cited by 60
Challenging and Complex Decisions in the Management of the BRCA Mutation Carrier
Stan, D. L., Shuster, L. T., Wick, M. J., Swanson, C. L., Pruthi, S., & Bakkum-Gamez, J. N. (2013) · Journal of Women s Health · doi:10.1089/jwh.2013.4407 · Cited by 60
Coleman, R. L., Enserro, D. M., Spirtos, N. M., Herzog, T. J., Sabbatini, P. J., Armstrong, D. K., Kim, B. S., Fujiwara, K., Walker, J. L., Flynn, P. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5501 · Cited by 58
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer
Richardson, D. L., Backes, F. J., Seamon, L. G., Zanagnolo, V. L., O’Malley, D. M., Cohn, D. E., Fowler, J. M., & Copeland, L. J. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.011 · Cited by 56
Monk, B. J., & Chan, J. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx451 · Cited by 53
Lindemann, K. Y., Kristensen, G. B., Mirza, M. R., Davies, L. C., Hilpert, F., Romero, I., Ayhan, A., Burges, A., Rubio, M. J., Raspagliesi, F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw238 · Cited by 40
Pfisterer, J., Dean, A. P., Baumann, K., Rau, J., Harter, P., Joly, F., Sehouli, J., Canzler, U., Schmalfeldt, B., Shannon, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy285.142 · Cited by 34
Falandry, C., Savoye, A.-M., Stefani, L., Tinquaut, F., Lorusso, D., Herrstedt, J., Bourbouloux, E., Floquet, A., Brachet, P. E., Zannetti, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.5508 · Cited by 32
Evaluation of microsatellite instability in women with epithelial ovarian cancer
Caliman, L. P., Tavares, R. L. C., Gouvêa, J. B., ASSIS, A. C. S. C. D., CUNHA, K. D. J. D. D., Braga, L. D. C., Silva, L. M., & Filho, A. L. D. S. (2012) · Oncology Letters · doi:10.3892/ol.2012.776 · Cited by 18
The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers
Lheureux, S., Mirza, M. R., & Coleman, R. L. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00347 · Cited by 18
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Moore, K. N., Angelergues, A., Konecny, G. E., García, Y., Banerjee, S., Lorusso, D., Lee, J.-Y., Moroney, J. W., Colombo, N., Roszak, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309169 · Cited by 494
A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer
Ye, Y., Dai, Q., & Qi, H. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00451-x · Cited by 451
Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer
Li, J., Hu, H., He, J., Hu, Y., Liu, M., Cao, B., Chen, D., Ye, X., Zhang, J., Zhang, Z., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101825 · Cited by 4
Metadata
- Authors
- Kuroki, L., & Guntupalli, S. R.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2020-11-09
- Volume
- 371
- Pages
- m3773
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3099043519
- Cited by
- 873
- References
- 117
- FWCI
- 73.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.